AU2002352477A1 - Sk-3 potassium channels and the treatment of sexual dysfunctions and/or vascular disorders - Google Patents

Sk-3 potassium channels and the treatment of sexual dysfunctions and/or vascular disorders

Info

Publication number: AU2002352477A1
Authority: AU; Australia
Prior art keywords: treatment; potassium channels; vascular disorders; sexual dysfunctions; dysfunctions
Prior art date: 2001-12-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2002352477A

Other versions

AU2002352477A8 (en

Inventor

Mark Chen

Derek Trezise

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Glaxo Group Ltd

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-21

Filing date

2002-12-19

Publication date

2003-07-15

2002-12-19 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2003-07-15 Publication of AU2002352477A8 publication Critical patent/AU2002352477A8/en

2003-07-15 Publication of AU2002352477A1 publication Critical patent/AU2002352477A1/en

Status Abandoned legal-status Critical Current

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Reproductive Health (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Hematology (AREA)
Gynecology & Obstetrics (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Marine Sciences & Fisheries (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
General Physics & Mathematics (AREA)

AU2002352477A 2001-12-21 2002-12-19 Sk-3 potassium channels and the treatment of sexual dysfunctions and/or vascular disorders Abandoned AU2002352477A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0130704.0		2001-12-21
GBGB0130704.0A GB0130704D0 (en)	2001-12-21	2001-12-21	New use
PCT/GB2002/005813 WO2003055505A2 (en)	2001-12-21	2002-12-19	Sk-3 potassium channels and the treatment of sexual dysfunctions and/or vascular disorders

Publications (2)

Publication Number	Publication Date
AU2002352477A8 AU2002352477A8 (en)	2003-07-15
AU2002352477A1 true AU2002352477A1 (en)	2003-07-15

Family

ID=9928209

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2002352477A Abandoned AU2002352477A1 (en)	2001-12-21	2002-12-19	Sk-3 potassium channels and the treatment of sexual dysfunctions and/or vascular disorders

Country Status (5)

Country	Link
EP (1)	EP1465650A2 (en)
JP (1)	JP2005524615A (en)
AU (1)	AU2002352477A1 (en)
GB (1)	GB0130704D0 (en)
WO (1)	WO2003055505A2 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TR199700930T2 (en) *	1995-03-14	1998-07-21	Vivus Incorporated	Method and kit to prevent erectile dysfunction.
US5731339A (en) *	1995-04-28	1998-03-24	Zonagen, Inc.	Methods and formulations for modulating the human sexual response
US6197801B1 (en) *	1998-01-14	2001-03-06	Usa Doctors Products, Inc.	Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction
FR2774593B1 (en) *	1998-02-12	2000-05-05	Philippe Gorny	OBTAINING A MEDICINE TO COMBAT FEMALE SEXUAL DYSFUNCTIONS
US6194447B1 (en) *	1998-07-02	2001-02-27	Neurosearch A/S	Bis (benzimidazole) derivatives serving as potassium blocking agents
US6486207B2 (en) *	1998-12-10	2002-11-26	Nexmed (Holdings), Inc.	Compositions and methods for amelioration of human female sexual dysfunction
CN1374861A (en) *	1999-04-06	2002-10-16	佐纳根有限公司	Methods for modulating the human sexual response
DE60005517T2 (en) *	1999-06-29	2004-07-01	Neurosearch A/S	POTASS CHANNEL BLOCKING AGENTS

2001
- 2001-12-21 GB GBGB0130704.0A patent/GB0130704D0/en not_active Ceased
2002
- 2002-12-19 EP EP02788193A patent/EP1465650A2/en not_active Withdrawn
- 2002-12-19 WO PCT/GB2002/005813 patent/WO2003055505A2/en not_active Ceased
- 2002-12-19 AU AU2002352477A patent/AU2002352477A1/en not_active Abandoned
- 2002-12-19 JP JP2003556081A patent/JP2005524615A/en active Pending

Also Published As

Publication number	Publication date
WO2003055505A2 (en)	2003-07-10
GB0130704D0 (en)	2002-02-06
AU2002352477A8 (en)	2003-07-15
WO2003055505A3 (en)	2003-11-27
JP2005524615A (en)	2005-08-18
EP1465650A2 (en)	2004-10-13

Publication	Publication Date	Title
WO2002086502A8 (en)	2003-03-20	Methods for the diagnosis and treatment of bone disorders
AU2002255248A1 (en)	2002-11-11	Diagnosis, treatment and research of mental disorders
MXPA03007816A (en)	2003-12-08	Disposable underpants and method of providing the same.
AU2002310256A1 (en)	2002-12-16	Ppp2cs as modifiers of the p53 pathway and methods of use
HUP0401023A3 (en)	2004-10-28	Use of flibanserin in the treatment of sexual disorders
PL366636A1 (en)	2005-02-07	Pyranoindazoles and their use for the treatment of glaucoma
AU2002247004A1 (en)	2002-07-30	Methods of diagnosis and treatment of osteoporosis
AU2002334870B8 (en)	2003-04-22	Combinations for the treatment of immunoinflammatory disorders
AU2003213787A1 (en)	2003-09-22	Compositions and methods for the treatment of anorectal disorders
EP1466175A4 (en)	2008-04-09	SPHKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2002363411A1 (en)	2003-05-19	Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
AU2002312315A1 (en)	2002-12-23	Microfabricated surgical devices and methods of making the same
GB0128674D0 (en)	2002-01-23	Treatment of sleep disorders and the like
AU2002363228A1 (en)	2003-05-12	Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
AU2002366195A1 (en)	2003-06-10	Use of bisindolmaleimide and gemcitabine for the treatment of cancer
AU2002352477A1 (en)	2003-07-15	Sk-3 potassium channels and the treatment of sexual dysfunctions and/or vascular disorders
AU2002240745A1 (en)	2002-09-19	Diagnosis and treatment of blood disorders
AU2003244437A1 (en)	2003-09-02	Quinoxalinones and their use especially in the treatment of cardiovascular diseases
AU2002350053A1 (en)	2003-05-12	Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943
AU3582101A (en)	2001-09-12	The treatment of functional gastrointestinal disorders
HK1060049A (en)	2004-07-30	The treatment of sexual dysfunction and cardiovascular disease with quinolinone enantiomers
AU2002952346A0 (en)	2002-11-14	Diagnosis and treatment of disorders
AU2002361654A8 (en)	2003-06-30	Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2002365654A1 (en)	2003-06-17	Treatment of diseases via the skin
AU2002348330A1 (en)	2003-05-12	Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 86604

Legal Events

Date	Code	Title	Description
2004-09-09	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase